心房細動（SPAF）治療における脳卒中予防の世界市場（～2026年）

• 英文タイトル：Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY04745
• 出版社/出版日：QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、95ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療機器・消耗品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は心房細動（SPAF）治療における脳卒中予防のグローバル市場について調査・分析したレポートです。種類別（経口直接トロンビン阻害剤、経口直接因子Xa阻害剤）市場規模、用途別（病院、クリニック、外来外科センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別心房細動（SPAF）治療における脳卒中予防の競争状況、市場シェア
・世界の心房細動（SPAF）治療における脳卒中予防市場：種類別市場規模 2015年-2020年（経口直接トロンビン阻害剤、経口直接因子Xa阻害剤）
・世界の心房細動（SPAF）治療における脳卒中予防市場：種類別市場規模予測 2021年-2026年（経口直接トロンビン阻害剤、経口直接因子Xa阻害剤）
・世界の心房細動（SPAF）治療における脳卒中予防市場：用途別市場規模 2015年-2020年（病院、クリニック、外来外科センター）
・世界の心房細動（SPAF）治療における脳卒中予防市場：用途別市場規模予測 2021年-2026年（病院、クリニック、外来外科センター）
・北米の心房細動（SPAF）治療における脳卒中予防市場分析：米国、カナダ
・ヨーロッパの心房細動（SPAF）治療における脳卒中予防市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの心房細動（SPAF）治療における脳卒中予防市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の心房細動（SPAF）治療における脳卒中予防市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの心房細動（SPAF）治療における脳卒中予防市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Boehringer Ingelheim、Bayer、Johnson & Johnson、Bristol-Myers Squibb、Pfizer、Daiichi-Sankyo、Gilead
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Atrial fibrillation (AF) now a days has become a common and serious condition affecting almost 1-2% of the total population of age group 65 years and above.
Increase in the aging population leads to increase in the prevalence further leads to increase rick of premature death.

Market Analysis and Insights: Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market
The global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Scope and Market Size
Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Boehringer Ingelheim
Bayer
Johnson & Johnson
Bristol-Myers Squibb
Pfizer
Daiichi-Sankyo
Gilead
…

Market segment by Type, the product can be split into
Oral Direct Thrombin Inhibitors
Oral Direct Factor Xa Inhibitors
Market segment by Application, split into
Hospitals
Clinics
Ambulatory Surgical Centers

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue
1.4 Market by Type
1.4.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Oral Direct Thrombin Inhibitors
1.4.3 Oral Direct Factor Xa Inhibitors
1.5 Market by Application
1.5.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Perspective (2015-2026)
2.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Growth Trends by Regions
2.2.1 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Market Size
3.1.1 Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Revenue (2015-2020)
3.1.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Concentration Ratio
3.2.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue in 2019
3.3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Key Players Head office and Area Served
3.4 Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product Solution and Service
3.5 Date of Enter into Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020)
5.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2015-2020)
6.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Key Players in North America (2019-2020)
6.3 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020)
6.4 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2015-2020)
7.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Key Players in Europe (2019-2020)
7.3 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020)
7.4 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020)

8 China
8.1 China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2015-2020)
8.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Key Players in China (2019-2020)
8.3 China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020)
8.4 China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2015-2020)
9.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Key Players in Japan (2019-2020)
9.3 Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020)
9.4 Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2015-2020)
10.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020)

11 India
11.1 India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2015-2020)
11.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Key Players in India (2019-2020)
11.3 India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020)
11.4 India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2015-2020)
12.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Boehringer Ingelheim
13.1.1 Boehringer Ingelheim Company Details
13.1.2 Boehringer Ingelheim Business Overview
13.1.3 Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
13.1.4 Boehringer Ingelheim Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020))
13.1.5 Boehringer Ingelheim Recent Development
13.2 Bayer
13.2.1 Bayer Company Details
13.2.2 Bayer Business Overview
13.2.3 Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
13.2.4 Bayer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020)
13.2.5 Bayer Recent Development
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Details
13.3.2 Johnson & Johnson Business Overview
13.3.3 Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
13.3.4 Johnson & Johnson Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020)
13.3.5 Johnson & Johnson Recent Development
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Details
13.4.2 Bristol-Myers Squibb Business Overview
13.4.3 Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
13.4.4 Bristol-Myers Squibb Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020)
13.4.5 Bristol-Myers Squibb Recent Development
13.5 Pfizer
13.5.1 Pfizer Company Details
13.5.2 Pfizer Business Overview
13.5.3 Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
13.5.4 Pfizer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020)
13.5.5 Pfizer Recent Development
13.6 Daiichi-Sankyo
13.6.1 Daiichi-Sankyo Company Details
13.6.2 Daiichi-Sankyo Business Overview
13.6.3 Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
13.6.4 Daiichi-Sankyo Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020)
13.6.5 Daiichi-Sankyo Recent Development
13.7 Gilead
13.7.1 Gilead Company Details
13.7.2 Gilead Business Overview
13.7.3 Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
13.7.4 Gilead Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020)
13.7.5 Gilead Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue
Table 3. Ranking of Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Oral Direct Thrombin Inhibitors
Table 6. Key Players of Oral Direct Factor Xa Inhibitors
Table 7. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Regions (2015-2020)
Table 11. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Growth Strategy
Table 17. Main Points Interviewed from Key Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players
Table 18. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Players (2015-2020) (Million US$)
Table 19. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Players (2015-2020)
Table 20. Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment as of 2019)
Table 21. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product Solution and Service
Table 24. Date of Enter into Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020) (Million US$)
Table 27. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Share by Type (2015-2020)
Table 28. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2021-2026)
Table 29. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Share by Application (2015-2020)
Table 30. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020) (Million US$)
Table 31. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Share by Application (2021-2026)
Table 32. North America Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share (2019-2020)
Table 34. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020) (Million US$)
Table 35. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2015-2020)
Table 36. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020) (Million US$)
Table 37. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2015-2020)
Table 38. Europe Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share (2019-2020)
Table 40. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2015-2020)
Table 42. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2015-2020)
Table 44. China Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (2019-2020) (Million US$)
Table 45. China Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share (2019-2020)
Table 46. China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020) (Million US$)
Table 47. China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2015-2020)
Table 48. China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020) (Million US$)
Table 49. China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2015-2020)
Table 50. Japan Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share (2019-2020)
Table 52. Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2015-2020)
Table 54. Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share (2019-2020)
Table 58. Southeast Asia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2015-2020)
Table 60. Southeast Asia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2015-2020)
Table 62. India Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (2019-2020) (Million US$)
Table 63. India Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share (2019-2020)
Table 64. India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020) (Million US$)
Table 65. India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2015-2020)
Table 66. India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020) (Million US$)
Table 67. India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share (2019-2020)
Table 70. Central & South America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type (2015-2020)
Table 72. Central & South America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application (2015-2020)
Table 74. Boehringer Ingelheim Company Details
Table 75. Boehringer Ingelheim Business Overview
Table 76. Boehringer Ingelheim Product
Table 77. Boehringer Ingelheim Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020) (Million US$)
Table 78. Boehringer Ingelheim Recent Development
Table 79. Bayer Company Details
Table 80. Bayer Business Overview
Table 81. Bayer Product
Table 82. Bayer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020) (Million US$)
Table 83. Bayer Recent Development
Table 84. Johnson & Johnson Company Details
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Product
Table 87. Johnson & Johnson Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020) (Million US$)
Table 88. Johnson & Johnson Recent Development
Table 89. Bristol-Myers Squibb Company Details
Table 90. Bristol-Myers Squibb Business Overview
Table 91. Bristol-Myers Squibb Product
Table 92. Bristol-Myers Squibb Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020) (Million US$)
Table 93. Bristol-Myers Squibb Recent Development
Table 94. Pfizer Company Details
Table 95. Pfizer Business Overview
Table 96. Pfizer Product
Table 97. Pfizer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020) (Million US$)
Table 98. Pfizer Recent Development
Table 99. Daiichi-Sankyo Company Details
Table 100. Daiichi-Sankyo Business Overview
Table 101. Daiichi-Sankyo Product
Table 102. Daiichi-Sankyo Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020) (Million US$)
Table 103. Daiichi-Sankyo Recent Development
Table 104. Gilead Company Details
Table 105. Gilead Business Overview
Table 106. Gilead Product
Table 107. Gilead Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2015-2020) (Million US$)
Table 108. Gilead Recent Development
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type: 2020 VS 2026
Figure 2. Oral Direct Thrombin Inhibitors Features
Figure 3. Oral Direct Factor Xa Inhibitors Features
Figure 4. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Ambulatory Surgical Centers Case Studies
Figure 8. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Report Years Considered
Figure 9. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Regions: 2020 VS 2026
Figure 11. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Players in 2019
Figure 14. Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue in 2019
Figure 16. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed

以下、関連資料のご紹介

心房細動（AF）治療の世界市場（～2026年）

Global Atrial Fibrillation Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY10917 2020年11月25日 99Pages
当調査資料は心房細動（AF）治療のグローバル市場について調査・分析したレポートです。種類別（薬品、非手術的処置、手術的処置）市場規模、用途別（病院、クリニック、外来手術センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、...

心房細動（AF）診断の世界市場（～2026年）

Global Atrial Fibrillation (AF) Diagnostics Market Size, Status and Forecast 2020-2026
MRC2-11QY10916 2020年11月25日 91Pages
当調査資料は心房細動（AF）診断のグローバル市場について調査・分析したレポートです。種類別（心電図（ECG）、心エコー図（エコー）、経食道心エコー検査（TEE）、胸部X線、血液検査、ストレス検査、電気的活動検査）市場規模、用途別（カーディオセンター、大病院、心臓専門医療企業）市場規模、地域別（北米、...

虚血性脳卒中予防治療薬の世界市場（～2026年）

Global Ischemic Cerebral Stroke Prevention Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY12446 2020年11月25日 92Pages
当調査資料は虚血性脳卒中予防治療薬のグローバル市場について調査・分析したレポートです。種類別（抗凝固療法、血行再建術、再灌流、抗血小板薬、神経保護薬）市場規模、用途別（病院、クリニック、緩和ケア、外来手術センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア...

心房細動薬の世界市場（～2026年）

Global Atrial Fibrillation Drugs Market Insights and Forecast to 2026
MRC2-11QY02728 2020年11月20日 146Pages
当調査資料は心房細動薬のグローバル市場について調査・分析したレポートです。種類別（抗不整脈薬、抗凝固薬）市場規模、用途別（発作性心房細動、持続性心房細動、長年の持続性心房細動）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、イ...

口唇ヘルペス治療・予防の世界市場（～2026年）

Global Treatment and Prevention of Herpes Labialis Market Size, Status and Forecast 2020-2026
MRC2-11QY04899 2020年11月20日 129Pages
当調査資料は口唇ヘルペス治療・予防のグローバル市場について調査・分析したレポートです。種類別（バラシクロビル、アシクロビル、ファムシクロビル、ドコサノール、その他）市場規模、用途別（外用、経口、注射）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジ...

虚血性脳卒中治療薬の世界市場（～2026年）

Global Ischemic Stroke Drugs Market Size, Status and Forecast 2020-2026
MRC2-11QY12447 2020年11月25日 99Pages
当調査資料は虚血性脳卒中治療薬のグローバル市場について調査・分析したレポートです。種類別（組織プラスミノーゲン活性化因子、抗凝固剤、抗血小板剤、降圧剤、その他）市場規模、用途別（病院、クリニック、外来手術センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、...

左心耳（LAA）閉鎖装置の世界市場（～2026年）

Global Left Atrial Appendage (LAA) Closure Market Size, Status and Forecast 2020-2026
MRC2-11QY12494 2020年11月25日 97Pages
当調査資料は左心耳（LAA）閉鎖装置のグローバル市場について調査・分析したレポートです。種類別（心外膜LAA閉鎖装置、心内膜LAA閉鎖装置）市場規模、用途別（病院、ASC、心臓クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中...

急性虚血性脳卒中治療薬の世界市場（～2026年）

Global Acute Ischemic Stroke Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY13563 2020年11月30日 98Pages
当調査資料は急性虚血性脳卒中治療薬のグローバル市場について調査・分析したレポートです。種類別（血栓溶解療法、降圧療法、抗血小板療法、抗凝固剤）市場規模、用途別（病院、外来手術センター、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア...

脳卒中管理の世界市場（～2026年）

Global Stroke Management Market Size, Status and Forecast 2020-2026
MRC2-11QY04744 2020年11月20日 97Pages
当調査資料は脳卒中管理のグローバル市場について調査・分析したレポートです。種類別（コンピュータ断層撮影スキャン（CTスキャン）、磁気共鳴画像法（MRI）、頸部超音波、脳血管造影、心電図、心エコー検査、その他）市場規模、用途別（虚血性脳卒中、出血性脳卒中）市場規模、地域別（北米、米国、カナダ、ヨーロッ...

脳卒中診断・治療の世界市場（～2026年）

Global Stroke Diagnostics and Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY04743 2020年11月20日 97Pages
当調査資料は脳卒中診断・治療のグローバル市場について調査・分析したレポートです。種類別（診断、治療）市場規模、用途別（虚血性脳卒中、出血性脳卒中）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中...

心房細動（AF）治療の世界市場（～2026年） Atrial fibrillation is an abnormal heart rhythm characterized by rapid and irregular beating of the atria. Often it starts as brief periods of abnormal beating which become longer and possibly constant over time. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting…
心房細動（AF）診断の世界市場（～2026年） Atrial fibrillation (AF) is a type of cardiac arrhythmia which is caused by irregular electrical activities in the atria. It may occur with no symptoms but most common ones associated with it are fainting, palpitations, congestive failure of the heart or chest pain. Factors such as aging of populati…
虚血性脳卒中予防治療薬の世界市場（～2026年） Market Analysis and Insights: Global Ischemic Cerebral Stroke Prevention Therapeutics Market The global Ischemic Cerebral Stroke Prevention Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Ischemic Cerebral…
心房細動薬の世界市場（～2026年） Market Analysis and Insights: Global Atrial Fibrillation Drugs Market The global Atrial Fibrillation Drugs market size is projected to reach US$ 6158 million by 2026, from US$ 5987 million in 2020, at a CAGR of 2.7%% during 2021-2026. Global Atrial Fibrillation Drugs Scope and Market Size Atrial Fib…
口唇ヘルペス治療・予防の世界市場（～2026年） Market Analysis and Insights: Global Treatment and Prevention of Herpes Labialis Market The global Treatment and Prevention of Herpes Labialis market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Treatment and Prevention of…